(Updated to include Wedbush commentary)
Wedbush increased Spyre Therapeutics' (SYRE) price target to $100 from $80 after the company released first clinical efficacy results for SPY002 for induction in ulcerative colitis patients.
The top-line results appear in-line with other members of the class, highlighting that the drug could work well in combination therapies, analysts led by David Nierengarten wrote in a Monday note.
Spyre Therapeutics has an average rating of buy and mean price target of $96.07, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $81.70, Change: $+0.91, Percent Change: +1.13%